Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses
N. Roth, J. Schoen, D. Hoffmann, M. Thran, A. Thess, S. O. Mueller, B. Petsch, S. Rauch
This study compares two mRNA vaccines, CVnCoV and CV2CoV, showing CV2CoV induces higher neutralizing antibody titers and cross-neutralization against variants in rats.
bioRxiv · May 13, 2021 · PreprintImmunology